Story excerpt provided by Columbus Business First.
Written by Carrie Ghose.
Navidea Biopharmaceuticals Inc. has signed a European distributor for its cancer diagnostic aid Lymphoseek that comes with a $2 million up-front payment, but sales on the continent aren’t expected to start until early next year.
Dublin-based Navidea (NYSEMKT:NAVB) entered an exclusive sublicense with SpePharm AG, a specialty pharmaceutical arm of Dutch distributor Norgine BV.
Click here to read the complete article.
Originally published March 5, 2015.